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Pig respiratory diseases are a major concern for modern swine producers worldwide, accounting for nearly 54% of deaths during the nursery phase ([@bib0028]). *Bordetella bronchiseptica* is one of the most important pathogens that can cause swine respiratory disease problems. It is the primary etiologic agent of atrophic rhinitis (AR), which is a contagious respiratory disease highly prevalent in swine nurseries worldwide ([@bib0021]). A general therapeutic strategy against AR is the use of antibiotic treatments in piglets. However, the increase in antibiotic resistant bacteria has driven research on the development of alternative solutions to protect piglets from diseases such as AR. Neonatal piglets are born with an incompetent immune system, and in the first hours of life they are only protected by postnatal transfer of passive immunity through lactation ([@bib0024]). Thus, the survival of neonatal piglets is highly reliant on the ingestion of colostrum within their first 18 to 36 h of life ([@bib0002]), and ingestion of milk once the colostrum is no longer present. It is, therefore, important to improve the transfer of passive immunity from sows to piglets, which can be achieved through the administration of immuno-stimulating products to the sow before farrowing ([@bib0029]).

Algal sulfated polysaccharide extracts (MSP) could provide an alternative prophylactic strategy that stimulate innate immune responses and limits infections in farm animals, and subsequently reduces the use of antibiotics ([@bib0004]). Seaweeds are an important source of bioactive compounds, such as MSPs, which are a complex group of macromolecules with a wide range of important biological properties ([@bib0017], [@bib0032], [@bib0033]). These water-soluble compounds can be found in the cell walls of seaweeds, and their structure and properties differ between the three major divisions of marine algae: Chlorophyceae, Phaeophyceae, and Rhodophyceae (green, brown, and red algae, respectively). In recent years, an increasing number of studies revealed that MSPs have a wide range of beneficial biological activities including antiviral, antioxidant, anticancer, anticoagulant, and anti-hyperlipidemic activities ([@bib0030], [@bib0031]). Moreover, several studies have demonstrated that MSP extracts from seaweeds exert immunomodulatory activities by modifying the activity of cytokines and macrophages that play a critical role in the innate immune system. This has been shown *in vitro* in murine macrophages ([@bib0010], [@bib0013], [@bib0014], [@bib0023]), but also *in vivo* in mice ([@bib0015], [@bib0020]), and using an *in vitro* system of porcine intestinal epithelial (IPEC-1) cells ([@bib0003]). It was recently demonstrated by [@bib0011], also to be the case for chickens, both *in vitro* on heterophils and monocytes and *in vivo* when the extract was administered *per os*. In particular, MSP extracted from green algae have shown immunomodulating properties, both as crude algal extracts and as highly purified fractions in different models, such as in murine macrophages *in vitro* ([@bib0014], [@bib0026], [@bib0027]), in mice and chicken *in vivo* ([@bib0011], [@bib0025]), and in turbot phagocyte and peritoneal leucocytes in *in vitro* and *in vivo* trials, respectively ([@bib0007]). Ulvans increase the production of reactive oxygen species and nitric oxide, the secretion of pro-inflammatory cytokines, such as tumor necrosis factor (TNFα), interleukin (IL)-1, IL-6, IL-8, IL-12, interferon (IFN) ([@bib0014], [@bib0015], [@bib0023]), and the expression of the cytokine (TGF-β) involved in IgA plasmocyte activation, and of CCL20, which is a chemokine known to regulate several aspects of intestinal immunity ([@bib0004], [@bib0003]). Seaweed extracts have therefore emerged as a rich source of bioactive natural compounds that can be used as a new generation of growth enhancers that simultaneously potentiate the immune function and improve animal health.

The current study evaluated the activity of a MSP extract from the green alga (*U. armoricana*) on the immune transfer between sows and piglets. Specifically, we analyzed the effects of adding different doses of MSP extract to sows feed during the final month of gestation on piglets' performance, as well as on the levels of anti-*Bordetella* immunoglobulin G (IgG) antibodies in colostrum, milk, and blood, and on total immunoglobulin A (IgA) in colostrum and milk of sows.

2. Materials and Methods {#sec0002}
========================

*U. armoricana* were collected on the beach at Plestin les Grèves (Brittany, France, 48°39′28″N 3°37′47″W), and its MSP extract was produced and analyzed as previously described ([@bib0004]). The presence of endotoxins was assessed using the kit Etoxate (Sigma, Lyon, France), and their levels were below the detection level of the kit (0.05--0.1 endotoxin units/mL).

Thirty-two sows (Large white × Landrace genetics) were housed on a commercial farm with a "farrow to finish" system. The sows were born on the farm, and at 170 days old they were transferred into quarantine and given the first vaccination against AR with 2 mL of inactivated vaccine per gilt (Porcilis AR-T DF; MSD animal health, Beaucouzé, France). Two booster inoculations with the same vaccine were administrated at 200 and 330 days old. The latter date corresponded to 30 days before the anticipated farrowing date ([Fig. 1](#fig0001){ref-type="fig"}). All sows received the same diet two times per day (8 a.m. and 5 p.m.) and were divided into four groups with 8 sows each: control group and three test groups with increasing MSP extract dosage (2 g/day, 8 g/day, and 16 g/day). To facilitate the distribution of MSP extract, crushed biscuit was added as excipient (40 g) to all groups. The excipient (control) or excipient-MSP extract complex (test) was administrated by top-dressing on the feed during two periods of three consecutive days: before the last vaccine booster against AR, and one week before farrowing ([Fig. 1](#fig0001){ref-type="fig"}). Cross fostering during the first two days of the piglets' life was a normal practice at the farm to improve piglet performance before weaning ([@bib0006]). Adoption was performed between sows within the same experimental group, and no sample collection or measurements were performed on the adopted piglets. All sows and piglets were housed and maintained in compliance with the French Ministry of Agriculture and Finishing standards for animal protection.Fig. 1Experimental timeline showing vaccination date, MSP extract supplementation periods, and sampling dates for blood, colostrum, and milk.Fig. 1.

At farrowing, the total number of piglets and the number of live piglets within each litter were recorded (litter size), as was the weight of all live-born piglets. The first four live piglets from each litter were immediately tagged and weighed individually and these piglets were weighed again at weaning (21 days after farrowing). Blood samples were collected from the vena cava of each sow and piglets at several time points ([Fig. 1](#fig0001){ref-type="fig"}). Samples were collected in 9 mL plastic tubes with the vacutainer system, and then centrifuged for 2 min at 3000× *g* (Labofuge 200, Thermo Fisher Scientific Inc., Waltham, MA, USA). Serum was separated and stored at −80°C for further processing. Colostrum (∼20 mL) was manually collected from each sow 2 h after the start of farrowing on the first 3 teats, and milk (∼30 mL) was manually collected from the same teats at 7 and 21 days after farrowing. Twenty I.U. (2 cc) of oxytocin (Ocytovem, CEVA animal health, Libourne, France) were injected intramuscularly on the neck of sows to facilitate milk collection. Colostrum and milk samples were frozen at −20°C immediately after collection, for posterior analyses.

Anti-*Bordetella* IgG was measured in the blood samples of sows and piglets and in the colostrum and milk via an anti-*Bordetella* ELISA test (IBL International, Hamburg, Germany) as previously described ([@bib0001]). Total IgA concentration was determined in milk with an ELISA quantification kit specific for pigs, according to the manufacturer\'s instructions (Bethyl Laboratories Inc., Montgomery, TX, USA). These analyses were performed by LDA 37 (Laboratoire Départemental d' Analyse de Touraine, 3 rue de l' Aviation, 37210 Parcay-Meslay, France).

Data normality was validated by the Kolmogorov--Smirnov test, and immunoglobulin concentrations were compared between experimental groups by Student\'s *t*-tests, applying Bonferroni corrections for multiple comparisons. The variations in immunoglobulin levels between the groups were examined by comparing the slopes of the regression lines using the *F* test; when the lines were parallel, their origins and elevations were also compared. Data are shown as average ± standard error of the mean (SEM) and differences were considered significant at *p* \< 0.05 in all tests. All statistical analyses were performed using GraphPad Prism 4.03 (GraphPad Software, San Diego, CA, USA).

3. Results and Discussion {#sec0003}
=========================

Searching for new bioactive natural compounds that potentiate the immune function of farmed animals has become an important area of research for modern swine producers worldwide. MSP present in the cell walls of green algae have important immunomodulating and immunostimulant properties, which can constitute a promising prophylactic supplement to improve farm animals' resistance against infectious diseases. The present study evaluated the immunomodulating effects of a MSP extract from the green alga *U. armoricana* on immunity transfer between sows and piglets, and provides evidence that supplementation with MSP can benefit maternal immunity.

The MSP extract used in the present study had no effect on litter performance, including litter size and individual piglet weight at birth and at 21 days old (*p*  0.05, supplemental data). This is in agreement with previous results ([@bib0012], [@bib0019]), and it is likely explained by MSP extract supplementation starting too late to promote a significant effect on piglets' early-stage performance. All experimental groups showed similar levels of IgG in sows' serum at days 34 and 23 before farrowing (*p* \> 0.05; [Fig. 2](#fig0002){ref-type="fig"}A). After the 3rd vaccination against AR at day 30, a tendency was observed for higher IgG in MSP-supplied groups, particularly at day 23 before farrowing and day 3 after farrowing. Thereafter, IgG continued to decrease until day 14 after farrowing for the three MSP extract groups (*p* \< 0.05). These results can be associated with the timing of blood sampling, which may not have been optimal to detect the maximum effect of MSP extract on IgG titers in the colostrum. Previous research has shown that IgG levels on blood should be measured on samples taken 3 weeks after vaccination ([@bib0016]). However, in the present study, 3 weeks after vaccination would be very close to the anticipated farrowing date. Although the IgG serum levels of the 14 day piglets were statistically similar among experimental treatments ([Table 1](#tbl0001){ref-type="table"}), results show a relatively higher level of IgG in piglets serum, thereby supporting a positive effect of MSP extract supplementation.Fig. 2Effect of algal sulfated polysaccharide (MSP extract) on the kinetics of immunoglobulin G (IgG) anti-*Bordetella* in the blood, colostrum, and milk of sows. (A) Levels in blood at 34 and 23 days before farrowing (−34 and −23, respectively) and at 3 and 14 days after farrowing. (B) Levels in colostrum as compared to blood level at day 23 before farrowing and in sows blood compared to colostrum. Values are given as means ± standard error of the mean (whiskers), and asterisks (\*) represent significant differences (*p* \< 0.05).Fig. 2.Table. 1Levels of immunoglobulin G (IgG) anti-*Bordetella* (mean ± S.E.M.) in sow colostrum and serum, and in piglet serum (at day 14 after farrowing), and immunoglobulin A (IgA) in sow colostrum observed in each experimental group.Table 1Ig classControl (no MSP extract)MSP1 (2 g/d)MSP2 (8 g/d)MSP3 (16 g/d)IgG (UI/mL)Colostrum (day 0)85.7 ± 8.1114.1 ± 17.3118.4 ± 19.4117.1 ± 13.2Gilts serum (day 14)7.7 ± 3.213.7 ± 5.113.9 ± 4.38.4 ± 6.5Piglets serum (day 14)17.8 ± 5.723.2 ± 7.125.1 ± 6.818 ± 6.4IgA in colostrum (day 0; mg/mL)12.5 ± 2.49.8 ± 1.811.2 ± 1.511.9 ± 2.8

Results suggest a significant increase in the transfer rate of IgG from sows' blood to colostrum ([Fig. 2](#fig0002){ref-type="fig"}B), particularly when MSP extract was supplemented at the highest dosage (MSP3; *p* \< 0.05). Although these findings are similar to that of [@bib0018], it is important to note that the latter study tested a seaweed extract from *Laminaria* spp. and a longer supplementation period (from day 109 of gestation until weaning). The transfer of IgG from blood to colostrum is controlled by the FcRn receptor ([@bib0008]), and an increase in the transfer rate of IgG might be attributed to either an increase in the speed of transfer by the receptor, or by an increased expression of the receptor on the mammary gland epithelial cells ([@bib0008]). Colostrum is known to be the primary source of passive immunity in piglets, via IgG transfer from the mother to the litter. The significant increase in the transfer rate of IgG from blood to colostrum in sows supplemented with MSP3 extract was not reflected in the sera of the nursing piglets ([Table 1](#tbl0001){ref-type="table"}). Nevertheless, the relative increase in IgG in colostrum of sows supplemented with MSP1 and MSP2 extracts was concurrent with the results observed for piglets ([Table 1](#tbl0001){ref-type="table"}). It is also important to note that no significant differences were detected in the levels of IgG in milk among the experimental groups at any of the sampling days (data not shown). However, this could be associated with some practices previously identified, such as the timing of MSP extract supplementation and the duration of the supplementation period.

Although IgG is the major isotype in sow serum and colostrum, IgA predominates in milk ([@bib0009]). Neonatal protection against local pathogens is mostly conferred by milk-derived immunity until weaning---the so-called lactogenic immunity. Almost 100% of colostrum IgG and 40% of colostrum IgA are derived from sow serum, while the majority of milk IgA (\>90%) results from a local synthesis in the mammary gland ([@bib0005]). While MSP extract supplementation had no effect on colostrum IgA concentration ([Table 1](#tbl0001){ref-type="table"}), total milk IgA level during lactation was higher in the MSP2 group than in the control group (*p* *\<* 0.03; [Fig. 3](#fig0003){ref-type="fig"}), which is in agreement with the results of [@bib0018] and [@bib0034]. The dose-dependent increase in milk IgA levels at days 7 and 21 ([Fig. 3](#fig0003){ref-type="fig"}) suggests an optimal dose of 8 g MSP extract per day, and this could be associated with the optimal dose to stimulate the transfer of IgA secreting plasmocytes to the mammary gland via the entero-mammary link. Although the *in vitro* analysis by [@bib0004] showed that MSP extract stimulates the expression of CCL20 (MIP3-α), which is a chemokine known to regulate several aspects of intestinal immunity, further studies are required to better establish the effect of MSP extracts on the immune entero-mammary link.Fig. 3Effect of algal sulfated polysaccharide (MSP extract) on immunoglobulin A (IgA) in sows' milk at days 7 and 21 after farrowing. Values are given as means (bars) ± standard error of the mean (whiskers), and asterisks (\*) represent significant differences (*p* \< 0.05).Fig. 3.

Results from the present study show that the intake of a MSP extract has positive immunomodulating effect on sows and piglets, even though further studies are needed to show an overall immunity effect and better resistance to infections. In addition, the mechanistic drivers of such immunomodulatory effects are not clear, as evidenced by the different immunoglobulin titers at particular pathways (e.g. milk and not colostrum), and for dose-specific supplementations in some cases. The present results can contribute to the development of alternative prophylactic solutions against respiratory diseases in swine production although further studies are needed to further explain the mode of action.
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